Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HARVARD BIOSCIENCE INCHBIO · Entity 7369 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HARVARD BIOSCIENCE INC
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,556 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 16,556 · Balance 37,556 F1: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier. F2: Includes (a) the award described in footnote (1) above, (b) 10,000 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on September 5, 2026. F3: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
F2: Includes (a) the award described in footnote (1) above, (b) 10,000 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on September 5, 2026.
F3: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 14:03 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 16,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-004058 · ownership.xml · nonDerivative · entry 1 DENELSKY STEPHEN J · CIK 0001204320 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,556 F1 · shares: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) 10,000 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on September 5, 2026. F3 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 18:13 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 10,000 | $4.87 | $48,700.00 |
DisclosureSEC source: 0001171843-26-001732 · ownership.xml · nonDerivative · entry 1 DENELSKY STEPHEN J · CIK 0001204320 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 F1 · balance_after: Includes (a) 10,000 shares of common stock purchased on March 17, 2026 and (b) 11,000 restricted stock units that fully vest on September 5, 2026. F2 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. Read SEC document |
| September 05, 2025 Filed Oct 7, 2025 17:28 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-006325 · ownership.xml · nonDerivative · entry 1 DENELSKY STEPHEN J · CIK 0001204320 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 F1 · shares: Represents an award of 110,000 restricted stock units that fully vest on September 5, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.